Several approaches successfully achieve allograft tolerance in preclinical models but are challenging to translate into clinical practice. Many clinically relevant factors can attenuate allograft tolerance induction, including intrinsic genetic resistance, peritransplant infection, inflammation, and preexisting antidonor immunity. The prevailing view for immune memory as a tolerance barrier is that the host harbors memory cells that spontaneously cross-react to donor MHC antigens. Such preexisting "heterologous" memory cells have direct reactivity to donor cells and resist most tolerance regimens. In this study, we developed a model system to determine if an alternative form of immune memory could also block tolerance. We posited that host memory T cells could potentially respond to donor-derived non-MHC antigens, such as latent viral antigens or autoantigens, to which the host is immune. Results show that immunity to a model nonself antigen, ovalbumin (OVA), can dramatically disrupt tolerance despite undetectable initial reactivity to donor MHC antigens. Importantly, this blockade of tolerance was CD8 + T cell-dependent and required linked antigen presentation of alloantigens with the test OVA antigen. As such, this pathway represents an unapparent, or "incognito," form of immunity that is sufficient to prevent tolerance and that can be an unforeseen additional immune barrier to clinical transplant tolerance.
Introduction
Clinical applications of tolerance-inducing therapeutics developed in preclinical transplantation models (1) (2) (3) (4) remain challenging to translate into clinical practice (5, 6) . Intrinsic genetic resistance (7) (8) (9) (10) , pathogen exposure (11, 12) , nonspecific immune stimulation (13, 14) , and preexisting immune memory (15, 16) each can impede the tolerance process. Alloreactive T cell memory can block transplant tolerance (15, (17) (18) (19) (20) (21) (22) in part because prior autoimmunity or exposure to pathogens or vaccines can generate populations of memory cells that cross-react to any given unrelated MHC allele. Because memory cells resist many tolerance-inducing treatments, this burden of donor MHC-reactive "heterologous" immunity represents an important clinical dilemma.
Here, we explored an alternative pathway for tolerance disruption by immune memory reactive to donor-derived non-MHC antigens. In clinical transplantation, donors often harbor latent infections with any number of different pathogens, such as Epstein-Barr virus (EBV) and cytomegalovirus (CMV) (23) (24) (25) (26) . Recipients can have corresponding immune memory to these nonself antigens, either through microbial exposure or via immunization. Alternatively, a subset of transplant recipients have underlying autoimmune diseases that generate immune memory to non-MHC antigens expressed in donor tissues. The consequence of such preexisting host immunity in allograft outcomes often is unclear. Specifically, it is not clear whether this form of immune memory is sufficient to disrupt tolerance induction.
We hypothesized that antigen-specific immune memory to donor-derived antigens could be sufficient to impair tolerance independent of antidonor MHC reactivity or host inflammation. To address this issue, we developed a generic model system in which immune memory was generated to a model nonself antigen, ovalbumin (OVA), and tested for potential impact on tolerance induction. Results demonstrate that anti-OVA memory could disrupt tolerance when OVA antigens were presented in association with donor cells. Importantly, tolerance disruption was CD8 + T cell-dependent, required linked presentation of alloantigens and the memory-directed antigen (OVA), and could occur independently of antidonor MHC alloreactivity within the memory CD8 + T cell pool. As such, this unapparent, or "incognito," immune memory represents an unanticipated and alternate form of host immunity capable of disrupting transplant tolerance. ), and BALB/cByJ (BALB/c) mice were purchased from the Jackson Laboratory (Bar Harbor, ME). B6-OVA and BALB/c mice were intercrossed, and OVA transgene-positive offspring were backcrossed with BALB/c mice for five or six generations to generate OVA-expressing transgenic BALB/c (BALB/c-OVA) mice. B6-CD45. 2 
Materials and Methods

Mice
OT-1 Rag1
À/À transgenic mice were purchased from Taconic Biosciences (Hudson, NY) and intercrossed with B6-CD45.1 mice to generate B6-CD45.1 OT-1 Rag1 À/À mice. All mice were maintained under specific pathogen-free conditions at the University of Colorado Anschutz Medical Campus (AMC). Except for BALB/c pancreatic islet donors, all experiments used mice that were bred in-house.
Vaccinations
To generate antigen-specific immunity, randomized groups of 8-to 12-weekold age-matched, co-housed B6 male littermates were injected intraperitoneally with one of three vaccinations. OVA/adjuvant-primed (OVA/Adj 0 ) mice received 200 lg endotoxin-free OVA (Sigma-Aldrich, St. Louis, MO) plus a subunit adjuvant of 50 lg polyinosinic-polycytidylic acid sodium salt (Sigma-Aldrich) and 50 lg agonistic CD40-specific antibody (FGK45, BioXCell, West Lebanon, NH) in phosphate-buffered saline, as previously described (27 
Detection of OVA-specific Ig
Immunolon II plates (ThermoScientific, Waltham, MA) were coated with 100 lg/mL OVA (Sigma-Aldrich) and blocked with 1% bovine serum albumin and 0.05% NaN 3 . Sera were serially diluted from 1:50 dilution and assayed for anti-OVA reactivity against the plates by incubation for 2 h at room temperature. Bound Ig was detected with a goat polyclonal antimouse Ig detection antibody conjugated to alkaline phosphatase (SouthernBiotech, Birmingham, AL) and visualized at 405 nm using a para-nitrophenyl phosphate substrate (Sigma-Aldrich) and Infinite 200 PRO plate reader (Tecan, Mannedorf, Switzerland).
Detection of donor-specific T cells
Purified splenic T cells were obtained using negative selection magnetic enrichment (Stemcell Technologies, Cambridge, MA). T cells were cultured for 18 h in serum-free medium at 1 9 10 3 to 2 9 10 5 cells/well and stimulated with 3 9 10 5 c-irradiated BALB/c, B6-OVA, or B6 splenocytes. IFNc-secreting cells were detected by enzyme-linked immunospot (ELISPOT) silver staining (U-Cytech biosciences, Urecht, Netherlands) and counted with use of a Bioreader 4000 Pro-X plate reader (Bio-Sys Laboratories, Pasadena, CA).
Alloantibody detection
Flow cytometric assessment of donor-reactive IgG antibodies was performed as previously described (28) 
Pancreatic islet cell transplantation
Islet isolation and transplantation was performed as previously described (29) . Briefly, female BALB/c donor pancreata were injected with collagenase (Type V [Sigma-Aldrich] or CIzyme RI [VitaCyte, Indianapolis, IN]), digested by static incubation at 37°C, and purified over Histopaque (Sigma-Aldrich) or Lympholyte 1.1 (Cedarlane Labs, Burlington, NC) gradients. 400-450 hand-picked islets were grafted in the left renal subcapsular space of streptozotocin-induced diabetic B6 recipient mice. Rejection was defined as the first day of consecutive hyperglycemic blood glucose values of >270 mg/dL. In long-term euglycemic hosts, confirmation of graft-dependent blood glucose control was determined with nephrectomy of the graft-bearing kidney followed by return to hyperglycemia.
Tolerance-promoting regimens
To induce allograft tolerance using anti-CD154 as a monotherapy or combined with donor-specific transfusion (DST), transplant recipients were injected intraperitoneally with CD154-specific monoclonal antibodies (MR-1, BioXCell) at 250 lg/dose either on days À1, 2, 7, and 9 (relative to day 0 transplant) or on days À7, À4, 0, and 4 with intravenous administration of 10 7 T cell-depleted donor splenocytes on day À7. Spleen cells from Memory OT-1 T cells 
Study approval
All animal care and experiments conformed to National Institutes of Health guidelines and were approved by the Institutional Animal Care and Use Committee at AMC.
Results
Vaccination generates robust OVA-reactive cellular and humoral immunity We generated preexisting host immunity to a model xenogeneic antigen in transplant recipients by vaccinating B6 mice with ovalbumin plus an adjuvant of anti-CD40 and polyinosinic-polycytidylic acid (27) . Control B6 mice were immunized with the adjuvant alone. OVA/adjuvantprimed (OVA/Adj 0 ) mice and control adjuvant-primed (Adj 0 ) mice were analyzed ranging from 4 to 19 weeks postvaccination for OVA-specific cellular and humoral immunity ( Figures 1A and B and S1 ). OVA/Adj 0 mice also developed tenfold higher titers of serum OVAspecific total Ig than did Adj 0 mice ( Figure 1C ). Thus, OVA-vaccinated mice generated robust anti-OVA cellular and humoral immunity.
OVA-vaccinated B6 mice develop limited crossreactivity to donor BALB/c MHC and are amenable to allograft tolerance induction Previous reports indicated that vaccinations or pathogen infections can generate heterologous immunity toward donor MHC (18) (19) (20) (21) 30 ) that can impair tolerance induction in preclinical transplant models (15, 31, 32) . We therefore assessed whether the OVA immunization in B6 mice generated elevated pretransplant heterologous immunity to the intended allograft donor strain, BALB/c. While purified splenic T cells from OVA/Adj 0 mice made a vigorous and rapid IFNc response to transgenic B6 cells that constitutively express OVA as a transmembrane protein (B6-OVA), they did not show elevated reactivity to allogeneic BALB/c cells relative to responses by splenic T cells from control Adj 0 mice ( Figure 2A ).
Given the potential importance of preexisting alloantibody in transplantation (33,34), we also determined whether the OVA vaccination generated detectable anti-BALB/c antibodies. Relative to sera from control Adj 0 mice, sera from OVA/Adj 0 mice did not significantly bind BALB/c target cells, despite high reactivity to OVA-expressing B6 target cells (B6-OVA) ( Figure 2B hi spleen cells from OVA/Adj 0 mice (n = 12) and Adj 0 mice (n = 7). (C) Serum titers of OVA-specific antibodies (total Ig) from OVA/Adj 0 mice (n = 7) compared with Adj 0 mice (n = 5) as determined by ELISA. Data were pooled from 12 independent experiments. Each symbol in (B) and (C) indicates the data from a single mouse. End-point titers in (C) were measured relative to a baseline normal value taken as the mean AE 3 SD of sera pooled from six nonvaccinated B6 mice. Bars represent mean AE SD. ***p < 0.001, unpaired two-tailed t statistical test.
We next determined whether anti-OVA memory affected acute rejection or tolerance induction to BALB/c islet allografts. Acute allograft rejection was comparable between untreated OVA/Adj 0 mice and control Adj 0 mice (Figure 2C) . Conversely, OVA vaccination did not prevent allograft tolerance induction, as BALB/c graft survival was not significantly different between OVA/Adj 0 mice and Adj 0 mice treated with CD154-specific monoclonal antibodies ( Figure 2D ). In stark contrast, allosensitized BALB/c 0 recipients demonstrated accelerated acute allograft rejection ( Figure 2C ) and complete disruption of allograft prolongation after anti-CD154 treatment (Figure 2D ). Taken together, data indicate that robust vaccine-induced anti-OVA immunity that is largely devoid of preexisting antidonor immunity can be innocuous for acute allograft rejection and tolerance.
Peritransplant bystander reactivation of OVA-specific memory does not impair allograft tolerance Considering that a variety of peritransplant events, including de novo microbial infections and reactivation of latent infections, can stimulate antigen-specific immunity and impair allograft survival and tolerance (11, 12, (35) (36) (37) , we explored whether bystander peritransplant reactivation of memory could affect tolerance induction. OVA/Adj 0 mice were challenged with B6-OVA cells 7 days before receiving BALB/c islet transplants and tolerance-promoting anti-CD154 ( Figure 3A ). The B6-OVA cell challenge expanded CD8 + CD44 hi tetramer + T cells even in the presence of anti-CD154 treatment ( Figure 3B ). Despite pronounced bystander reactivation and expansion of OVA-specific memory CD8 + T cells, recipients could nevertheless be tolerized to BALB/c islet allografts ( Figure 3C ).
"Linked" presentation of donor antigens and vaccine-directed antigens disrupts tolerance induction In contrast to tolerance disruption by alloreactive memory (31, (38) (39) (40) , at this point it would appear that OVA-specific immune memory is essentially irrelevant to allograft immunity and tolerance. However, donors can often express non-MHC antigens, such as pathogenderived antigens or autoantigens, to which the host is immune. Host reactivity to donor-associated non-MHC antigens could be innocuous or could represent an alternate means through which immune memory can impair tolerance. Therefore, using our vaccination model, we explored conditions whereby donor-derived cells expressing memory-directed antigens might block tolerance induction in immune recipients without apparent preexisting immunity to donor MHC.
For proof-of-principle studies, we used a standard tolerization protocol (41, 42) in which recipients were treated pretransplant with anti-CD154 therapy plus varied forms of DST ( Figure 4A ). After treatment with anti-CD154 therapy and BALB/c DST cells that did not express OVA antigens, OVA-vaccinated mice and control-vaccinated mice showed similar survival of transplanted BALB/c allografts ( Figure 4B) . Next, to model the scenario of recipient exposure to donor-derived cells that also express non-MHC memory-directed antigens, OVA-immune mice were treated with BALB/c DST cells that transgenically express OVA (BALB/c-OVA). When treated with BALB/c-OVA DST plus anti-CD154, control Adj 0 recipients still accepted transplanted BALB/c islets. In striking contrast, OVA-vaccinated mice displayed a profound disruption of allograft prolongation, with 14 of 16 animals showing acute allograft rejection ( Figure 4C ).
We hypothesized that tolerance disruption required "linkage" of donor MHC and memory-directed antigens on the same donor-derived cells. "Linked" recognition is a well-known property in which T cells can affect either activation (43, 44) or inhibition (45-48) of other T cells interacting with the same antigen presenting cell (APC). To address this issue, we determined the impact of delivering BALB/c and OVA antigens on separate sets of DST cells as a form of "unlinked" antigen presentation. After sequential treatment with B6-OVA then BALB/c DST plus anti-CD154 therapy, OVA/Adj 0 mice and control Adj 0 mice predominantly accepted BALB/c allografts (Figure 4D) . These results indicate that tolerance disruption requires physical linkage of donor and memory-directed antigens on the same donor cells.
The BALB/c-OVA DST resulted in tolerance blockade in the absence of the memory-directed antigen (OVA) on the islet transplant itself, implying that the recognition of OVA was inciting a response to the linked BALB/c alloantigens despite anti-CD154 treatment. We posited that OVA-specific memory T cells interacted with host APCs that copresented alloantigens during the initial phase of tolerance induction. Therefore, we next determined the degree and timing of donor-specific alloreactivity potentially triggered by anti-OVA immunity. While one might expect that anti-OVA memory would rapidly license antidonor reactivity in response to BALB/c-OVA DST, this was not the case. ELISPOT analysis for splenic antidonor IFNc production indicated that BALB/c-OVA DST alone (without anti-CD154) triggered robust alloimmunity within 7 days after DST (day 0 of transplantation) in both OVA/Adj 0 and Adj 0 mice ( Figure 4E ). In contrast, treatment with BALB/c-OVA DST plus anti-CD154 strongly inhibited initial peritransplant alloimmunity in both OVA/Adj 0 and Adj 0 animals during the same time period ( Figure 4E ). After islet transplantation, host splenic antidonor reactivity continued to be restrained in OVA/ Adj 0 recipients relative to Adj 0 mice at 7 days posttransplant ( Figure 4F , p = NS). However, a clear demarcation emerged between Adj 0 and OVA/Adj 0 animals as the latter group progressed toward allograft rejection. Graft rejection in OVA/Adj 0 animals (during a period of 8-47 days) was associated with significant antidonor IFNc production by splenic T cells, while paired, nonrejecting Adj 0 control animals showed continued restraint of antidonor reactivity ( Figure 4G ). Interestingly, a concomitant production of alloreactive antibodies did not occur in either vaccination group after treatment with DST plus anti-CD154 and transplantation (data not shown). Thus, OVA-specific memory did not trigger an immediate allogeneic T cell response after BALB/c-OVA DST and anti-CD154 therapy, but, instead, this response developed To illustrate that DST treatment is not an essential component for this model, we conducted ancillary studies using heart allografts from bone marrow chimeras in which BALB/c donors harbored OVA-expressing hematopoietic cells (denoted as BALB/c-OVA-BALB/c chimeras; Figure S2A ). We found that BALB/c-OVA-BALB/c chimeric heart allografts readily disrupted anti-CD154-specific prolongation of graft survival in OVA-vaccinated animals but not in control-vaccinated recipients (Figure S2B ). These results demonstrate that the donor graft itself is capable of introducing tolerance-disrupting antigens without a requirement for DST.
Taken together, we find that when donor cells express memory-directed antigens, it is possible for host preexisting immunity to incite alloreactivity and markedly disrupt allograft tolerance induction. We refer to this kind of immune memory as "incognito" memory, because conventional assays for detecting initial antidonor reactivity would fail to identify this potential barrier for transplantation, yet it can covertly and unexpectedly disrupt tolerance induction during host exposure to donor and memory-directed linked antigens.
CD8-dependent "incognito" memory blocks tolerance induction
Because OVA-vaccinated recipients harbor both OVAspecific cellular and humoral immunity, we next determined whether vaccine-induced memory T cells, antibodies, or both were necessary for "incognito" memory to block tolerance induction. To this end, we selectively prevented the initial development of CD4-or CD8-dependent immune memory by depleting either CD4 + T cells or CD8 + T cells during initial vaccination ( Figure 5A ). Four weeks after T cell depletion and vaccination, T cell populations in CD4-depleted mice, but 
cells (no significant difference). (E-G) Frequencies of interferon (IFN)c-producing donor-specific (anti-BALB/c) splenic T cells from
OVA-vaccinated mice were detected by ELISPOT at (E) 7 days after treatment with tolerance-promoting therapies (BALB/c-OVA DST and anti-CD154, given as described in [A]), (F) 7 days after transplantation with BALB/c islets, or (G) the time of allograft rejection by OVA/Adj 0 mice (control paired Adj 0 mice were nonrejectors). Data were pooled from three to nine independent experiments. Bars represent mean AE SEM of quadruplicate measurements from OVA/Adj 0 mice (n = 3-9 per treatment) and Adj 0 mice (n = 3-9 per treatment). ***p < 0.001, Kaplan-Meier method with the log-rank test and Cox regression model (A-D), *p < 0.05, multiple unpaired t statistical tests for individual treatments and time points (E-G).
not CD8-depleted mice, had reconstituted to nearly normal levels ( Figure S3A ). Consistent with previous results indicating that our vaccination protocol generates antigen-specific memory CD8 + T cells without CD4 + T cell help (49), CD4-depleted OVA/Adj 0 mice developed splenic CD8 + CD44 hi tetramer + T cells that rapidly produced IFNc in response to OVA-expressing B6 cells (B6-OVA) ( Figure 5B ). Moreover, CD4-depleted OVA-vaccinated mice did not develop detectable OVA-specific antibodies ( Figure 5C ). Conversely, CD8-depleted OVA/Adj 0 mice generated high titers of OVAspecific antibodies without developing memory CD8 + T cells ( Figures 5B and C) . Thus, vaccinated recipients developed selective CD8 + cellular memory or humoral immune memory in CD4-or CD8-depleted mice, respectively.
Mice with selective CD4-or CD8-dependent anti-OVA memory were then tested for their respective propensity for allograft tolerance induction after treatment with BALB/c-OVA DST/anti-CD154 therapy. Vaccine-induced memory generated in the absence of CD4 + T cells still markedly disrupted tolerance in seven of seven OVA/Adj 0 animals despite the absence of detectable anti-OVA antibodies ( Figure 5D ). Conversely, memory generated in the absence of CD8 + T cells failed to disrupt tolerance ( Figure 5E ), despite both the presence of high-titer anti-OVA antibodies ( Figure 5C ) and the ability of these mice to acutely reject BALB/c islets when not treated with a tolerance-promoting therapy ( Figure S3B ). Therefore, CD8-dependent, and not CD4-dependent, components of vaccine-induced immunity were essential for "incognito" memory to disrupt tolerance.
"Incognito" memory CD8 + T cells do not require heterologous immunity to block tolerance We next determined whether memory CD8 + T cells that definitively lacked the capacity for antidonor heterologous immunity could be sufficient to disrupt allograft tolerance. To achieve this goal, we used OT-1 Rag1 À/À T cell receptor transgenic mice, which generate OVA 257-264 -specific CD8 + T cells that are not cross-reactive to BALB/ c targets in vitro and do not reject BALB/c skin allografts in vivo (data not shown). Antigen-experienced OT-1 
Rag1
À/À cells were adoptively transferred into na€ ıve B6 recipients to generate mice with OVA-reactive memory CD8 + T cells lacking donor cross-reactivity ( Figure 6A ). Memory OT-1 cells engrafted into host B6 mice at similar or somewhat lower frequencies compared with endogenous CD8 + tetramer + T cells detected in the blood of OVA/Adj 0 mice ( Figure 6B ) and had similar phenotypic profiles as vaccine-induced memory cells ( Figure S4 ).
Animals bearing transferred memory OT-1 cells (denoted as OT1 M mice) were treated with either control BALB/c DST or OVA-expressing BALB/c (BALB/c-OVA) DST plus anti-CD154 and subsequently transplanted with BALB/c islets. Transferred memory OT-1 T cells did not affect BALB/c allograft survival when recipients were treated with BALB/c DST plus anti-CD154 therapy ( Figure 6C ). However, when recipients were treated with BALB/c-OVA DST plus anti-CD154 therapy, memory OT-1 T cells disrupted long-term allograft survival in nine of nine OT1 M mice ( Figure 6C ). Memory OT-1 T cells were required for these results because B6 mice accepted the majority of their grafts when they were not adoptively transferred with OT-1 T cells but were treated with BALB/c-OVA DST plus anti-CD154 therapy and transplanted with BALB/c islets ( Figure 6C ). Taken together, these data demonstrate that memory CD8 + T cells incapable of heterologous donor reactivity are nevertheless sufficient to block tolerance induction in this model system.
Discussion
Conventional screening assays test for cellular and humoral host reactivity to donor MHC molecules but may not predict host immune responses to donor-associated non-MHC antigens, such as microbe-derived antigens or autoantigens. In this study, we determined the impact of immunity to donor-derived non-MHC antigens on tolerance induction. Specifically, we tested the hypothesis that host immunity to non-MHC antigens can disrupt allograft tolerance independently of donor MHC-reactive heterologous immunity. It was essential that our study design distinguish between antigen-specific reactivity and nonspecific host inflammation in attenuating allograft tolerance. While peritransplant host immune stimulation by either pathogens (11, 12) or toll-like receptor agonists (13, 14) can prevent tolerance, the ability of preexisting immune memory itself to impair tolerance may be more variable and less apparent. Therefore, we studied the impact of memory on tolerance induction independently of tolerance-disrupting pathogen-associated stimuli. We modeled a common clinical scenario in which donor cells harbor non-MHC antigens to which the recipient is immune. By linking a model xenogeneic antigen (OVA) to donor cells, we found that host anti-OVA T cell immunity impaired tolerance and incited the activation of alloreactive T cells despite tolerance-inducing treatments. This type of unapparent, or "incognito," antigen-specific immune memory was sufficient to dramatically disrupt allograft tolerance.
The observed capacity for host anti-OVA immunity to disrupt allograft tolerance had a number of specific properties. First, the vaccination that generated anti-OVA immunity did not generate detectable donor-specific heterologous immunity and had no discernable impact on either immunity or tolerance to an allograft. Even secondary exposure to OVA-expressing cells during the peritransplant period was insufficient to disrupt tolerance induction by anti-CD154 therapy. These results illustrate the potentially innocuous impact of antigen-specific immune memory on tolerance induction, because even a simultaneous bystander response to OVA-bearing cells was insufficient to impair allograft tolerance provided that OVA antigens were not expressed on donor cells.
Second, seemingly benign immune memory can have severe consequences on tolerance induction if toleranceinducing donor cells harbor the memory-directed antigen. This inhibition of tolerance required "linked" expression of donor MHC and the immunizing antigen on the same DST inoculums. While other transplant tolerance studies indicate a role for linked suppression of differing antigens on the same APC for promoting tolerance (45, 48, 50) , the current results illustrate the key converse property of linked immune activation (44, 51, 52) . Importantly, the activating property of the memory cell population appears dominant to the tolerizing property of anti-CD154 toward the linked, unrelated alloantigens. Thus, we propose that preexisting immunity to OVA results in the dominant disruption of tolerance to other linked antigens in the microenvironment during initial alloantigen encounter.
Third, an essential feature of our model involved the expression of the test antigen (OVA) on the initial tolerogen (DST) but not on the subsequent islet transplant. If the donor graft expressed OVA, then tolerance disruption could be the result of tolerance-resistant memory cells directly contributing to allograft rejection. The DST model demonstrated the principle that OVA immunity could incite gradual immunity to unrelated alloantigens akin to epitope spreading (53) . Ancillary studies using heart allografts from bone marrow chimeric donors showed that the expression of OVA antigens by donor hematopoietic cells could incite tolerance disruption in OVA/Adj 0 animals. Thus, a donor graft itself can introduce tolerancedisrupting antigens without a requirement for DST.
Surprisingly, CD8
+ T cells and not CD4 + T cells or antibodies were necessary for this particular form of tolerance blockade. Prior studies showed that alloreactive memory CD4 + T cells could confer tolerance resistance (16, 54) . Moreover, in animal models using a similar costimulation blockade approach, memory B cells and antidonor MHC antibodies can block cardiac allograft tolerance (33, 34) . In those studies, humoral immunity was directed toward donor MHC molecules. Importantly, Burns et al demonstrated that antidonor MHC antibodies could disrupt tolerance via linked recognition with other alloantigens, similar to the process we observed in the current study (34) . In contrast, we found that tolerance could be induced despite high anti-OVA antibody titers. The difference in the specificity of memory T cells and preformed antibodies for donor non-MHC antigens versus MHC antigens could be an important distinction between these differing studies. Moreover, CD8
+ T celldependent memory may not be a universal feature of how donor non-MHC-directed immunity can impair tolerance. The mechanisms through which donor expression of microbial antigens or autoantigens activate specific humoral or cellular immunity in the host might dictate which immune memory pathways dominate in disrupting tolerance.
A key question centers on how this type of immune memory results in tolerance blockade. Developing or expanding cross-reactive cells from populations of memory CD8 + T cells was not required to prevent tolerance, because OVA-specific OT-1 Rag1 À/À CD8 + memory T cells that do not exhibit detectable donor reactivity were sufficient to confer tolerance resistance in na€ ıve B6 hosts. Given that memory OT-1 T cells could not react to the donor MHC to directly mediate graft rejection, the ability of this type of "incognito" immune memory to prevent tolerance is best explained by classic linked recognition, in which memory cells respond to APCs that simultaneously present OVA antigens and donor antigens ( and subsequently trigger the activation of donor-reactive T cells that are pathogenic to the graft. We envision that memory blockade interferes with an as-yet-unidentified checkpoint during fate decision toward tolerance. "Incognito" memory does not immediately license the activation of donor-reactive T cells after DST in the presence of anti-CD154 treatment ( Figure 4E ) or result in accelerated allograft rejection ( Figure 4C) . Instead, the licensing of donor reactivity occurs more gradually, indicating a change in ongoing T cell fate decision from tolerance to immunity ( Figure 7 ). We must emphasize that "incognito" memory is not a new phenotype or subset of memory T cells. We use the term "incognito" simply to connote the pathway and consequences of memory cell responses to donor non-MHC antigens that can be unapparent pretransplant yet still disrupt transplant tolerance induction.
Although we intentionally developed a generic model to illustrate a principle of tolerance disruption by memory cells, the results raise an important dilemma for the prospect of inducing allograft tolerance in most settings of conventional transplantation. The donor will likely harbor a number of metagenome-encoded antigens (55) to which the recipient may have preexisting immunity that could be deleterious to future tolerance-promoting regimens. Of course, the tissue distribution of pathogen-associated antigens could influence whether immune memory disrupts tolerance induction. In the current study, we modeled one scenario in which the nonself antigen was restricted to hematopoietic cells, as would occur in EBV infection (25) . In another example, recipients may be intentionally vaccinated against donor-derived pathogens, such as CMV, and then transplanted with pathogeninfected donor organs (56). An inadvertent consequence of eliciting protective CMV-reactive immune memory is that "linked antigen" reactivity could incite graft rejection in the immune host. It would be intriguing in future studies to determine if hematopoietic versus parenchymal distributions of donor nonself antigens have differing effects on tolerance induction in the immune host. Finally, in the setting of autoimmunity, preexisting memory to non-MHC autoantigens might also invoke tolerance disruption and trigger the development of alloimmunity due to copresented alloantigens and autoantigens. This process could partly explain the severe resistance of autoimmune recipients to allografts. Taken together, "incognito" memory represents an additional and potentially significant barrier to transplantation tolerance that is characterized by not requiring demonstrable pretransplant antidonor MHC heterologous immunity. 
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Data S1: Supplemental materials and methods. + cells at levels comparable to those of intact BALB/c-OVA mice (n = 4). (B) OVA-specific memory blocks tolerance induction by anti-CD154 monotherapy after transplantation of heart allografts from OVA-expressing BALB/c bone marrow chimeras (BALB/c-OVA-BALB/ c) (n = 5). Results are compared with OVA-vaccinated recipients of control BALB/c-BALB/c bone marrow chimeric heart allografts (n = 7). *p < 0.05, Kaplan-Meier method with the log-rank test and Cox regression model. 
